X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The ability to ‘mix and match’ vaccine platforms through this new joint venture and ImmunityBio’s multiple COVID vaccine platforms represents one of the most exciting approaches to ending COVID-19 including hAd5 S+N.
Lead Product(s): hAd5 S+N
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: ImmunityBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 03, 2022
Details:
The Amyris/IDRI RNA technology may also support the potential for intranasal vaccine delivery that can protect against SARS-CoV-2 and other respiratory diseases, including the flu.
Lead Product(s): RNA Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Infectious Disease Research Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 20, 2021
Details:
Preliminary data from a pre-clinical study of IDRI's Nanostructured Lipid Carrier (NLC) vaccine platform demonstrated a significant level of antibody production against the COVID-19 spike protein using a self-adjuvanting RNA vaccine.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Infectious Disease Research Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
